Alvine Pharmaceuticals has dosed the first randomized study patient in the CeliAction Study, a Phase IIb study of its lead clinical candidate, ALV003, which is in development for the treatment of patients with celiac disease. ALV003 is an orally administered mixture of two gluten-specific proteases shown in vitro to degrade gluten, the primary immunologic trigger for celiac disease. The CeliAction Study will evaluate the safety and efficacy of ALV003 at different dose levels administered during...